Brain and Behavior Discussion Group
The New York Academy of Sciences
Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.
DONATEPosted February 20, 2020
For decades, Alzheimer's disease (AD) research has focused on amyloid beta (Ab) aggregation as the main driver of disease and a promising target for treatment. However, the recent failure of multiple Phase III clinical trials focused on Ab have highlighted the need for different approaches. Many researchers are now working to uncover alternative mechanisms that contribute to disease, and potential treatments that can target these pathways. Reflecting the complexity of the disease, promising pathways are diverse and include neuroinflammation, tau propagation, and metabolic processes. Since AD is a heterogeneous and progressive disease, researchers are also working to develop biomarkers that can identify patients at the appropriate disease stage for a specific therapeutic. Learn more about recent breakthroughs in understanding Alzheimer's disease in this summary of our November 20th, 2019 symposium, which gathered the world’s leaders in the field.